Search Results - "Schindler, Suzanne E"

Blood-based biomarkers for Alzheimer’s disease: Current state and future use in a transformed global healthcare landscape by Hampel, Harald, Hu, Yan, Cummings, Jeffrey, Mattke, Soeren, Iwatsubo, Takeshi, Nakamura, Akinori, Vellas, Bruno, O’Bryant, Sid, Shaw, Leslie M., Cho, Min, Batrla, Richard, Vergallo, Andrea, Blennow, Kaj, Dage, Jeffrey, Schindler, Suzanne E.

“…Timely detection of the pathophysiological changes and cognitive impairment caused by Alzheimer’s disease (AD) is increasingly pressing because of the advent…”
Get full text

Assessment of Racial Disparities in Biomarkers for Alzheimer Disease by Morris, John C, Schindler, Suzanne E, McCue, Lena M, Moulder, Krista L, Benzinger, Tammie L S, Cruchaga, Carlos, Fagan, Anne M, Grant, Elizabeth, Gordon, Brian A, Holtzman, David M, Xiong, Chengjie

“…Racial differences in molecular biomarkers for Alzheimer disease may suggest race-dependent biological mechanisms. To ascertain whether there are racial…”
Get more information

Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging by Schindler, Suzanne E., Gray, Julia D., Gordon, Brian A., Xiong, Chengjie, Batrla-Utermann, Richard, Quan, Marian, Wahl, Simone, Benzinger, Tammie L.S., Holtzman, David M., Morris, John C., Fagan, Anne M.

“…Levels of amyloid β peptide 42 (Aβ42), total tau, and phosphorylated tau-181 are well-established cerebrospinal fluid (CSF) biomarkers of Alzheimer's disease,…”
Get full text

The performance of plasma amyloid beta measurements in identifying amyloid plaques in Alzheimer's disease: a literature review by Brand, Abby L, Lawler, Paige E, Bollinger, James G, Li, Yan, Schindler, Suzanne E, Li, Melody, Lopez, Samir, Ovod, Vitaliy, Nakamura, Akinori, Shaw, Leslie M, Zetterberg, Henrik, Hansson, Oskar, Bateman, Randall J

“…The extracellular buildup of amyloid beta (Aβ) plaques in the brain is a hallmark of Alzheimer's disease (AD). Detection of Aβ pathology is essential for AD…”
Get full text

CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer’s disease by Horie, Kanta, Salvadó, Gemma, Barthélemy, Nicolas R., Janelidze, Shorena, Li, Yan, He, Yingxin, Saef, Benjamin, Chen, Charles D., Jiang, Hong, Strandberg, Olof, Pichet Binette, Alexa, Palmqvist, Sebastian, Sato, Chihiro, Sachdev, Pallavi, Koyama, Akihiko, Gordon, Brian A., Benzinger, Tammie L. S., Holtzman, David M., Morris, John C., Mattsson-Carlgren, Niklas, Stomrud, Erik, Ossenkoppele, Rik, Schindler, Suzanne E., Hansson, Oskar, Bateman, Randall J.

“…Aggregated insoluble tau is one of two defining features of Alzheimer’s disease. Because clinical symptoms are strongly correlated with tau aggregates, drug…”
Get full text

Cerebrospinal fluid neurofilament light chain is a marker of aging and white matter damage by Meeker, Karin L., Butt, Omar H., Gordon, Brian A., Fagan, Anne M., Schindler, Suzanne E., Morris, John C., Benzinger, Tammie L.S., Ances, Beau M.

“…Cerebrospinal fluid (CSF) neurofilament light chain (NfL) reflects neuro-axonal damage and is increasingly used to evaluate disease progression across…”
Get full text

GPS driving: a digital biomarker for preclinical Alzheimer disease by Bayat, Sayeh, Babulal, Ganesh M, Schindler, Suzanne E, Fagan, Anne M, Morris, John C, Mihailidis, Alex, Roe, Catherine M

“…Abstract Background Alzheimer disease (AD) is the most common cause of dementia. Preclinical AD is the period during which early AD brain changes are present…”
Get full text

Advances in blood biomarkers for Alzheimer disease (AD): A review by Assfaw, Araya Dimtsu, Schindler, Suzanne E, Morris, John C

“…Alzheimer disease (AD) and Alzheimer Disease and Related Dementias (AD/ADRD) are growing public health challenges globally affecting millions of older adults,…”
Get full text

Photo-activatable Cre recombinase regulates gene expression in vivo by Schindler, Suzanne E., McCall, Jordan G., Yan, Ping, Hyrc, Krzystof L., Li, Mingjie, Tucker, Chandra L., Lee, Jin-Moo, Bruchas, Michael R., Diamond, Marc I.

“…Techniques allowing precise spatial and temporal control of gene expression in the brain are needed. Herein we describe optogenetic approaches using a…”
Get full text

Emerging cerebrospinal fluid biomarkers in autosomal dominant Alzheimer's disease by Schindler, Suzanne E., Li, Yan, Todd, Kaitlin W., Herries, Elizabeth M., Henson, Rachel L., Gray, Julia D., Wang, Guoqiao, Graham, Danielle L., Shaw, Leslie M., Trojanowski, John Q., Hassenstab, Jason J., Benzinger, Tammie L.S., Cruchaga, Carlos, Jucker, Mathias, Levin, Johannes, Chhatwal, Jasmeer P., Noble, James M., Ringman, John M., Graff-Radford, Neill R., Holtzman, David M., Ladenson, Jack H., Morris, John C., Bateman, Randall J., Xiong, Chengjie, Fagan, Anne M.

“…Four less well-studied but promising “emerging” cerebrospinal fluid (CSF) biomarkers are elevated in late-onset Alzheimer disease (AD): neurogranin,…”
Get full text

Neuropsychological measures that detect early impairment and decline in preclinical Alzheimer disease by Schindler, Suzanne E., M.D., Ph.D, Jasielec, Mateusz S., M.S, Weng, Hua, Ph.D, Hassenstab, Jason J., Ph.D, Grober, Ellen, Ph.D, McCue, Lena M., Ph.D, Morris, John C., M.D, Holtzman, David M., M.D, Xiong, Chengjie, Ph.D, Fagan, Anne M., Ph.D

“…Abstract Identifying which neuropsychological measures detect early cognitive changes associated with Alzheimer disease (AD) brain pathology would be helpful…”
Get full text

Design and feasibility of an Alzheimer's disease blood test study in a diverse community‐based population by Li, Melody, Li, Yan, Schindler, Suzanne E., Yen, Daniel, Sutcliffe, Siobhan, Babulal, Ganesh M., Benzinger, Tammie L. S., Lenze, Eric J., Bateman, Randall J.

“…INTRODUCTION Alzheimer's disease (AD) blood tests are likely to become increasingly important in clinical practice, but they need to be evaluated in diverse…”
Get full text

Baseline levels and longitudinal changes in plasma Aβ42/40 among Black and white individuals by Xiong, Chengjie, Luo, Jingqin, Wolk, David A., Shaw, Leslie M., Roberson, Erik D., Murchison, Charles F., Henson, Rachel L., Benzinger, Tammie L. S., Bui, Quoc, Agboola, Folasade, Grant, Elizabeth, Gremminger, Emily N., Moulder, Krista L., Geldmacher, David S., Clay, Olivio J., Babulal, Ganesh, Cruchaga, Carlos, Holtzman, David M., Bateman, Randall J., Morris, John C., Schindler, Suzanne E.

“…Blood-based biomarkers of Alzheimer disease (AD) may facilitate testing of historically under-represented groups. The Study of Race to Understand Alzheimer…”
Get full text

Multimodal brain age estimates relate to Alzheimer disease biomarkers and cognition in early stages: a cross-sectional observational study by Millar, Peter R, Gordon, Brian A, Luckett, Patrick H, Benzinger, Tammie L S, Cruchaga, Carlos, Fagan, Anne M, Hassenstab, Jason J, Perrin, Richard J, Schindler, Suzanne E, Allegri, Ricardo F, Day, Gregory S, Farlow, Martin R, Mori, Hiroshi, Nübling, Georg, Bateman, Randall J, Morris, John C, Ances, Beau M

“…Estimates of 'brain-predicted age' quantify apparent brain age compared to normative trajectories of neuroimaging features. The brain age gap (BAG) between…”
Get full text

Comparison of plasma and CSF biomarkers in predicting cognitive decline by Aschenbrenner, Andrew J., Li, Yan, Henson, Rachel L., Volluz, Katherine, Hassenstab, Jason, Verghese, Philip, West, Tim, Meyer, Matthew R., Kirmess, Kristopher M., Fagan, Anne M., Xiong, Chengjie, Holtzman, David, Morris, John C., Bateman, Randall J., Schindler, Suzanne E.

“…Objectives Concentrations of amyloid‐β peptides (Aβ42/Aβ40) and neurofilament light (NfL) can be measured in plasma or cerebrospinal fluid (CSF) and are…”
Get full text

Falls: a marker of preclinical Alzheimer disease: a cohort study protocol by Bollinger, Rebecca M, Keleman, Audrey, Thompson, Regina, Westerhaus, Elizabeth, Fagan, Anne M, Benzinger, Tammie LS, Schindler, Suzanne E, Xiong, Chengjie, Balota, David, Morris, John C, Ances, Beau M, Stark, Susan L

“…IntroductionProgression to symptomatic Alzheimer disease (AD) occurs slowly over a series of preclinical stages. Declining functional mobility may be an early…”
Get full text

CSF sTREM2: marking the tipping point between preclinical AD and dementia? by Schindler, Suzanne E, Holtzman, David M

“…Biomarkers for Alzheimer's disease (AD) have improved our understanding of the temporal sequence of biological events that lead to AD dementia (Jack et al ,…”
Get full text

Predicting cognitive decline: Which is more useful, baseline amyloid levels or longitudinal change? by Chen, Gengsheng, McKay, Nicole S., Gordon, Brian A., Liu, Jingxia, Joseph-Mathurin, Nelly, Schindler, Suzanne E., Hassenstab, Jason, Aschenbrenner, Andrew J., Wang, Qing, Schultz, Stephanie A., Su, Yi, LaMontagne, Pamela J, Keefe, Sarah J., Massoumzadeh, Parinaz, Cruchaga, Carlos, Xiong, Chengjie, Morris, John C., Benzinger, Tammie L.S.

“…The use of biomarkers for the early detection of Alzheimer’s disease (AD) is crucial for developing potential therapeutic treatments. Positron Emission…”
Get full text

Predicting continuous amyloid PET values with CSF and plasma Aβ42/Aβ40 by Wisch, Julie K., Gordon, Brian A., Boerwinkle, Anna H., Luckett, Patrick H., Bollinger, James G., Ovod, Vitaliy, Li, Yan, Henson, Rachel L., West, Tim, Meyer, Mathew R., Kirmess, Kristopher M., Benzinger, Tammie L.S., Fagan, Anne M., Morris, John C., Bateman, Randall J., Ances, Beau M., Schindler, Suzanne E.

“…Introduction Continuous measures of amyloid burden as measured by positron emission tomography (PET) are being used increasingly to stage Alzheimer's disease…”
Get full text

11 Clinical Manifestations of Neuroaxonal Injury by Keleman, Audrey A., Wisch, Julie K., Bollinger, Rebecca M., Schindler, Suzanne E., Morris, John C., Ances, Beau M., Stark, Susan L.

“…OBJECTIVES/GOALS: The preclinical stage of Alzheimer disease (AD) is a clinically silent period that can be detected through neuroimaging and biofluid…”
Get full text